Dr Reddy’s On Semaglutide Canada Opportunity: “We have a good chance”

Dr Reddy’s hopes to be the “first one in the pack”, when Ozempic loses patent cover next year in markets like Canada, where the semaglutide opportunity is projected at $2bn. Openings for the product in 80 smaller markets also loom, it said, but the GLP-1 agonist won’t ‘replace’ generic Revlimid and all business levers will have to grow.